Aarkstore - Metastatic Renal Cell Carcinoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

1
Aarkstore - Metastatic Renal Cell
Carcinoma-Global API Manufacturers, Marketed and
Phase III Drugs Landscape, 2015
Category Pharmaceuticals and Healthcare
2
Metastatic Renal Cell Carcinoma-Global API
Manufacturers, Marketed and Phase III Drugs
Landscape, 2015, Report provides comprehensive
insights about phase III pipeline drugs and
marketed drugs across the Metastatic Renal Cell
Carcinoma. A key objective of DelveInsights
report is to establish the understanding for API
Manufacturers for marketed and Phase III Pipeline
drugs across the different countries and regions
for the drugs falling under Metastatic Renal Cell
Carcinoma. The Report gives insights into patents
providing thepatent protection data and marketing
exclusivity of all the drugs across the
Metastatic Renal Cell Carcinoma. While the
leading brands, companies and chemicals are
considered thoroughly, DelveInsights report also
provides details on the Global API Manufacturers
across the globe covering Drug Master
FilingsofUS, Europe and API Manufacturers in Asia
specifically China and India. The research
analysis also presents the global sales forecasts
data till 2016.
Browse Complete Report http//www.aarkstore.com
/pharmaceuticals-healthcare/98056/metastatic-renal
-cell-carcinoma-global-api-manufacturers-marketed-
and-phase-iii-drugs-landscape-2015
3
Data Sources

• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis by
  DelveInsight team of industry experts.
• Secondary sources information and data has been
  collected from various printable and
  non-printable sources like search engines, News
  websites, Government Websites, Trade Journals,
  White papers, Magazines, Trade associations,
  Books, Industry Portals, Industry Associations
  and access to available databases.
• Please note This report requires certain
  updates. We have all the information available
  but require 3 business days to complete the
  process and ensure it is as up-to-date as
  possible. Certain sections in the report may be
  removed or altered based on the availability and
  relevance of data for the indicated disease.
• .

4
Scope

• A snapshot of the global Market therapeutics
  scenario for Metastatic Renal Cell Carcinoma.
• A review of the marketed products under
  prescription for Metastatic Renal Cell Carcinoma,
  regulatory information and marketing status.
• Coverage of global patent coverage and detailed
  commentaries on the US patent challenges.
• Graphical representation of investigational
  products for patent expiry and market
  exclusivities across the globe.
• Product profiles for marketed products for
  Metastatic Renal Cell Carcinoma with complete
  description of mechanism of action, therapeutic
  class, target, route(s) of administration and
  chemical details.
• Coverage of API Manufacturers for Metastatic
  Renal Cell Carcinoma drugs in the United States,
  Europe and Asian Regions with location details.
• Coverage of Regulatory filings in theUS, Europe,
  and Asia specifically India and China for
  Metastatic Renal Cell Carcinoma drugs.

5
Reasons to buy

• Evaluate the marketing status and exclusivity
  details of Metastatic Renal Cell Carcinoma key
  products to exploit opportunities for generic
  drug development opportunities.
• Identify and understand important and diverse
  types of therapeutics under Phase III development
  for Metastatic Renal Cell Carcinoma.
• Design effective counter-strategies to gain
  competitive advantage by identifying the key
  patent expiry details and exclusivity with
  respect to Metastatic Renal Cell Carcinoma.
• API intelligence over marketed drugs for
  Metastatic Renal Cell Carcinoma and gaining
  primary intelligence over active ingredients
  manufacturers across the globe.
• API intelligence over leading Phase III Pipeline
  drugs.
• Develop and design strategies by identifying the
  API manufacturers for Phase III Pipeline products
  to enhance and expand business potential and
  scope.

6
Table of Content

• Indication Overview
• Marketed Drugs
• Marketed Details of Drugs by Application Type
• Marketed Details of Drugs (NDA) by Marketing
  Status
• Marketed Details of Drugs by Patent Expiration
  Timeline
• Active Pharmaceutical Ingredient (API)
  Manufacturers Assessment
• API Manufacturers by United States Drug Master
  File (US DMF) Status
• API Manufacturers by US DMF Status (Drug
  Specific)
• API Manufacturers in Europe by Country
• API Manufacturers in India by State
• API Manufacturers in China by Province
• Marketed Details of Approved Drugs by Geography
• Active Pharmaceutical Ingredient (API)
  Manufacturers Assessment for Phase III Pipeline
  Drugs

7
List of Tables

• Metastatic Renal Cell Carcinoma Therapeutic
  Market, US, Marketed Drugs by Application Type,
  2015
• Metastatic Renal Cell Carcinoma Therapeutic
  Market, US, Marketed Drugs by Marketing Status,
  2015
• Metastatic Renal Cell Carcinoma Therapeutic
  Market, US, (Year), 2015
• Metastatic Renal Cell Carcinoma Marketed Drugs,
  API Manufacturers by US DMF Status, 2015
• Metastatic Renal Cell Carcinoma Marketed Drugs,
  US DMF Status Drug Specific (Number), 2015
• Metastatic Renal Cell Carcinoma Drugs, API
  Manufacturers, Europe by Country, 2015
• Metastatic Renal Cell Carcinoma Drugs, API
  Manufacturers, India by State, 2015
• Metastatic Renal Cell Carcinoma Drugs, API
  Manufacturers, China by Province, 2015
• Metastatic Renal Cell Carcinoma Drugs, API
  Manufacturers by Geography 2015
•  
•  

8
List of Figures

• Metastatic Renal Cell Carcinoma Therapeutic
  Market, US, Marketed Drugs by Application Type
  (), 2015
• Metastatic Renal Cell Carcinoma Therapeutic
  Market, US, Marketed Drugs by Marketing Status
  (), 2015
• Metastatic Renal Cell Carcinoma Therapeutic
  Market, US, (Year), 2015
• Metastatic Renal Cell Carcinoma Marketed Drugs,
  API Manufacturers by US DMF Status (), 2015
• Metastatic Renal Cell Carcinoma Marketed Drugs,
  US DMF Status Drug Specific (Number), 2015
• Metastatic Renal Cell Carcinoma Drugs, API
  Manufacturers, Europe by Country, 2015
• Metastatic Renal Cell Carcinoma Drugs, API
  Manufacturers, India by State, 2015
• Metastatic Renal Cell Carcinoma Drugs, API
  Manufacturers, China by Province, 2015

9
Related reports

•  
• Partnerships, Licensing, Investments and MA
  Deals and Trends for January 2015 in
  Pharmaceuticals
• EpiCast Report Sepsis - Epidemiology Forecast to
  2023
• Myasthenia Gravis Global Clinical Trials Review,
  H1, 2015
• Acute Renal Failure (ARF) (Acute Kidney Injury)
  Global Clinical Trials Review, H1, 2015
• OpportunityAnalyzer Dengue Vaccines -
  Opportunity Analysis and Forecasts to 2020 -
  Event-Driven Update
• Global Epinephrine Autoinjector Market 2015-2019
• Human Growth Hormone Market in the US 2015-2019
• Global Acute Coronary Syndrome (ACS) Market
  2015-2019
• Global Automated External Defibrillator Market
  2015-2019
• Global Gaucher Disease Market 2015-2019

10

• Metastatic Renal Cell Carcinoma-Global API
  Manufacturers, Marketed and Phase III Drugs
  Landscape, 2015
• Published Feb 2015 100 Pages
• Metastatic Renal Cell Carcinoma-Global API
  Manufacturers, Marketed and Phase III Drugs
  Landscape, 2015, Report provides comprehensive
  insights about phase III pipeline drugs and
  marketed drugs across the Metastatic Renal Cell
  Carcinoma.
• Price

Format Price
PDF 2000
Site License 4000
Enterprise Wide License 6000
11
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news